Sanara MedTech Inc. SMTI
Regular-session close
After hours · Nov 17, 4:01 PM ET
- YTD
- +40.17%
- 1 year
- +55.34%
- Market cap
- 300.55M
- Revenue (ttm)
- 78.06M
- Profit margin
- -10.71%
- EPS (ttm)
- -0.28
- Shares out
- 8.74M
- Forward P/E
- -29.15
- YTD return
- +40.17%
- 1-year return
- +55.34%
- Volume
- 91.11K
- Avg volume
- 185.27K
- Open
- 32.33
- Previous close
- 32.76
- Day's range
- 32.33 – 32.83
- 52-week range
- 16.05 – 35.52
- Beta
- 1.56
- Price target
- 44.00 (+34.4%)
Key statistics
- 50-day average
- 34.51
- 200-day average
- 32.48
- Enterprise value
- 309.72M
- Price / sales
- 3.82
- Price / book
- 7.50
- Revenue growth
- 35.20%
- Free cash flow
- 1.72M
- Total cash
- 16.28M
- Total debt
- 31.92M
- Return on equity
- -20.28%
- Short % of float
- 6.15%
Fundamental scorecard
6 of 25 checks passed on SMTI’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.34 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | -0.41 | — | — |
| Aug 12, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.21 | — | — |
| Mar 25, 2024 | Dec 1, 2023 | 0.00 | -0.03 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | init | — | Buy |
| May 15, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Mar 27, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Feb 6, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 15, 2023 | Cantor Fitzgerald | main | Overweight | Overweight |
| Sep 26, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Sanara MedTech Inc.
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- sanaramedtech.com
News
Your note
Sign in to keep a note on SMTI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DESUTTER ROBERT ANDREW | Director | Stock Award(Grant) | Jun 11, 2024 | 19,455 |
| MACK ROSZELL III | Director | Stock Award(Grant) | Jun 11, 2024 | 13,101 |
| MAJOR ERIC D | Director | Stock Award(Grant) | Jun 11, 2024 | 6,109 |
| MYERS KEITH G | Director | Stock Award(Grant) | Nov 10, 2024 | 1,975 |
| NIXON RONALD THOMAS | Chief Executive Officer | Stock Award(Grant) | Jun 11, 2024 | 3,473,100 |
| ORTWEIN SARA N | Director | Stock Award(Grant) | Jun 11, 2024 | 17,522 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 3.30% | 206,862 | 7.06M | Sep 29, 2024 |
| Vanguard Group Inc | 2.76% | 173,012 | 5.90M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.41% | 88,271 | 3.01M | Sep 29, 2024 |
| State Street Corporation | 0.94% | 58,688 | 2.00M | Sep 29, 2024 |
| Northern Trust Corporation | 0.65% | 40,458 | 1.38M | Sep 29, 2024 |
| Janney Montgomery Scott LLC | 0.52% | 32,846 | 1.12M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.53% | 95,714 | 3.26M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.51% | 94,653 | 3.23M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.66% | 41,239 | 1.41M | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.66% | 41,331 | 1.41M | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.57% | 35,601 | 1.21M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.32% | 20,112 | 686.02K | Oct 30, 2024 |
